G1 Therapeutics, Inc. - GTHX STOCK NEWS

G1 Therapeutics, Inc. (GTHX) has announced a webcast and conference call to discuss its third-quarter 2021 corporate and financial update, scheduled for November 3, 2021, at 8:30 a.m. ET. The company focuses on developing therapies for cancer treatment, including its first commercial product, COSELA™ (trilaciclib). G1 is pursuing a tumor-agnostic development strategy for COSELA, targeting various solid tumors such as colorectal, breast, lung, and bladder cancers. Interested parties can access the call via phone or through the company's website.

G1 Therapeutics, Inc. (GTHX) reported findings from a retrospective analysis of trilaciclib, revealing significant reductions in supportive care therapies for chemotherapy-induced myelosuppression in extensive-stage small-cell lung cancer (ES-SCLC) patients. The analysis indicated that administering trilaciclib prior to chemotherapy decreased severe neutropenia to 11.4% and grade 3/4 anemia to 20.3% compared to 52.9% and 31.9% in the placebo group, respectively. This could lessen hospitalizations and overall treatment burden, highlighting trilaciclib's potential in improving patient outcomes and reducing healthcare costs associated with chemotherapy.

G1 Therapeutics, Inc. (GTHX) announced the grant of inducement stock options for 62,100 shares to six new employees on October 1, 2021. These options, part of the Inducement Plan compliant with Nasdaq Listing Rule 5635(c)(4), are priced at $13.57 per share, aligning with the closing stock price on the grant date. The options vest over four years, beginning with 25% after the first anniversary and then monthly. G1 Therapeutics is focused on next-generation cancer therapies, including its product COSELA, and has a robust pipeline targeting various solid tumors.

G1 Therapeutics announced the effectiveness of the new J-code for COSELA™ (trilaciclib), a reimbursement code for outpatient care, as of October 1, 2021. The J-code J1448 standardizes billing for COSELA across Medicare, Medicaid, and commercial plans, enhancing patient access to this treatment for extensive-stage small cell lung cancer. Additionally, a new technology add-on payment for COSELA also took effect. CEO Jack Bailey emphasized the importance of timely access to COSELA, which decreases chemotherapy-induced myelosuppression.

G1 Therapeutics (GTHX) announced the hiring of a 15-person oncology sales force to enhance efforts in top-tier accounts aimed at increasing sales of COSELA (trilaciclib), following a collaboration with Boehringer Ingelheim. This initiative targets accounts that treat up to 50% of small cell lung cancer patients. Additionally, the company adopted a 2021 Sales Force Inducement Equity Incentive Plan allocating 500,000 shares for its new sales staff, approved without stockholder consent.

G1 Therapeutics, a commercial-stage oncology company, will participate in two virtual investor conferences in September 2021. On September 10, G1 will attend the Citi 16th Annual BioPharma Virtual Conference, which does not include a webcast. On September 13, CEO Jack Bailey will present at the H.C. Wainwright 23rd Annual Global Investment Conference, with a webcast available on demand. G1 Therapeutics focuses on developing therapies to improve cancer patients' lives, with a clinical pipeline including COSELA™ for various solid tumors.

G1 Therapeutics (GTHX) has granted inducement stock options to eight new employees, totaling 43,400 shares under its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $15.32 per share and a vesting schedule of 25% on the first anniversary, followed by monthly vesting over four years. This grant is part of G1's strategy to attract talent and complies with Nasdaq Listing Rule 5635(c)(4). G1 Therapeutics focuses on developing innovative therapies for cancer, including its first product, COSELA™.

G1 Therapeutics (GTHX) reported a total revenue of $6.6 million for Q2 2021, including $2.5 million from COSELA (trilaciclib) sales. The company initiated a pivotal Phase 3 trial for COSELA in metastatic TNBC and Phase 2 trials in NSCLC and bladder cancer. COSELA received Fast Track designation from the FDA for TNBC treatment. Despite the revenue growth, the net loss was $39.4 million, a rise from $31.2 million year-over-year. Cash and cash equivalents were $244 million, expected to sustain operations into 2023.

G1 Therapeutics, Inc. (GTHX) announced that the Centers for Medicare & Medicaid Services has approved a new technology add-on payment for COSELA™ (trilaciclib), effective October 1, 2021. This payment provides up to $5,526.30 in addition to standard Medicare reimbursements for hospitals administering COSELA to eligible patients. This decision follows the recent receipt of a C Code and permanent J Code for COSELA. CEO Jack Bailey stated that this decision enhances patient access to COSELA, addressing a vital need in treating extensive-stage small cell lung cancer.